Emodin

PreclinicalSmall molecule

Emodin is one of 33 small molecule programs targeting Autosomal Dominant Polycystic Kidney Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autosomal Dominant Polycystic Kidney DiseaseActive, not recruiting

Autosomal Dominant Polycystic Kidney DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Autosomal Dominant Polycystic Kidney Disease

#DrugCompanyPhaseTrials

Samsca

Otsuka

Approved

11 2

Afinitor

Novartis

Approved

1 3

Jardiance

Boehringer Ingelheim

Approved

3 4

Lanreotide Acetate

AAlbireo, an Ipsen Company

Approved

—5

Lesinurad

EEsperion Therapeutics, Inc.

Approved

—6

Versed

CConrado Roberto Hoffmann Filho

Sandostatin

Aldactone

1 9

Rapamune

PPrism Pharmaceuticals

Phase 3

4 10

Octreotide

Johnson & Johnson

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Autosomal Dominant Polycystic Kidney Disease1 trial

Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease

Terminated·ZZhi-Hong Liu, M.D.·N/A·NCT00801268·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Emodin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Emodin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Emodin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhi-Hong Liu, M.D. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: ZZhi-Hong Liu, M.D.

Emodin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Autosomal Dominant Polycystic Kidney Disease1 trial

References

Drug Info

Quick Facts

Related News